Lincoln Pharmaceuticals’ net profit surged 24.51% to Rs 23.67 crore for Q1 FY25, up from Rs 19.01 crore in the same quarter last year. Total income rose 10% to Rs 157.69 crore. EBITDA increased by 16.65% to Rs 33.14 crore. The company’s domestic and export operations performed well, and it aims for Rs 750 crore in revenue by FY26 through strategic growth and market expansion. Strong profit and income growth reflect effective strategies and robust market performance, boosting investor confidence in Lincoln Pharmaceuticals’ future prospects.
